Leigh MacConell

机构：Mirati Therapeutics (United States), Fate Therapeutics (United States)

发表论文 141 篇 · 总被引 7575 次 · h-index 31

代表论文

• Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019 · The Lancet · 被引 1263)
• A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis (2020 · Journal of Hepatology · 被引 196)
• CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients (2019 · Liver International · 被引 161)
• REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis (2019 · Contemporary Clinical Trials · 被引 126)
• Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis (2019 · Clinical Gastroenterology and Hepatology · 被引 105)
• An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations (2023 · Hepatology · 被引 30)